All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your MPN Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
2024 ASH Annual Meeting congress feed
Bookmark this article
To update you on the exciting content presented at the 66th ASH Annual Meeting and 
Exposition, December 7–10, 2024, San Diego, US., we have collated our social media coverage. Catch up with our social media relating to MPN here.
CONGRESS | #ASH24 | Susanne Isfort @SIsfort @MHH_life shares data revealing significant discrepancies between physician and patient perspectives symptom burden; emphasizing the need for inclusion of PROs in routine assessment of #MPN.
— MPN_Hub (@MPN_Hub) December 8, 2024
Follow our live feed for more updates:… pic.twitter.com/aQAZVSTnB4
CONGRESS | #ASH24 | Alessia Campagna,@HumanitasMilano discusses the clinical relevance of the gut microbiome and metabolomics in myeloid neoplasms, concluding that these analyses are crucial to identify biomarkers which can help predict relapse and the risk of infections… pic.twitter.com/zLpcyvYZtJ
— MPN_Hub (@MPN_Hub) December 8, 2024
CONGRESS #ASH24 | PRESENTATION
— MPN_Hub (@MPN_Hub) December 8, 2024
Haifa Kathrin Al-Ali, Universitätsklinikum Halle presented results from the phase III FREEDOM2 of fedratanib in pts with MF and low platelets. Pts treated with fedratanib had earlier and higher increases in platelet count from baseline. There was no… pic.twitter.com/E08STmAkbR
CONGRESS #ASH24 | PRESENTATION@KuykendallMd, @MoffittNews discussed a phase II study of fedratanib in pts with MDS, MPN, or CNL. Most common AEs included lipase elevation and diarrhoea. Median duration of therapy was 10.8 months, median survival has not yet been reached as many… pic.twitter.com/eSJUnlkWll
— MPN_Hub (@MPN_Hub) December 8, 2024
CONGRESS | #ASH24 | PRESENTATION
— MPN_Hub (@MPN_Hub) December 9, 2024
Marta Santaliestra @HematologiaMT shares findings from an analysis of the prognostic impact of achieving complete hematological response (CHR) and resistance/intolerance (R/I) to HU in patients from the Spanish registry of ET (N = 1,080).
CHR… pic.twitter.com/uIxY2Vb35b
CONGRESS #ASH24 | PRESENTATION
— MPN_Hub (@MPN_Hub) December 8, 2024
John Mascarenhas, @IcahnMountSinai discussed results from the phase III BOREAS study. Navtemadlin treatment improved biomarkers of disease burden in pts with R/R MF, including changes in CD34+ counts, driver mutation burden, and serum inflammatory… pic.twitter.com/xmHhlrud59
CONGRESS | #ASH24 | PRESENTATION
— MPN_Hub (@MPN_Hub) December 9, 2024
Francesca Palandri @Unibo shares findings on thrombosis risk stratification among PV patients undergoing HU treatment in the PV-ARC study (N = 1,162).
ELN criteria for therapy start effectively identify PV pts at increased thrombotic risk,… pic.twitter.com/wi9DozASxG
CONGRESS | #ASH24 | PRESENTATION
— MPN_Hub (@MPN_Hub) December 9, 2024
Shivani Handa @shivanihanda92 @MountSinaiNYC reports outcomes from outcomes of the largest cohort of TP53+ MPN pts to date in comparison with HMR mut, and identify a VAF cut-off associated with highest risk of progression to MPN-AP/BP (N =… pic.twitter.com/clmNkCRhNt
CONGRESS | #ASH24 | PRESENTATION
— MPN_Hub (@MPN_Hub) December 9, 2024
Ayalew Tefferi @MayoCancerCare shares findings from a review of the prognostic relevance of TP53MT in MPN, specified by subtype and disease stage (N = 115).
The presence of multi-hit TP53MT or MK/CK, in MF-CP, and possibly in ET/PV, warrants… pic.twitter.com/O5ADgSYhcK
CONGRESS | #ASH24 | PRESENTATION
— MPN_Hub (@MPN_Hub) December 9, 2024
Nico Gagelmann @NicoGagelmann, University Medical Center Hamburg, aimed to develop a uniform decision model to define optimal treatment timing in MF pts based on clinical and genomic information based on retrospective findings (N = 1,813).
The… pic.twitter.com/8vGRjr2isB
CONGRESS | #ASH24 | PRESENTATION
— MPN_Hub (@MPN_Hub) December 9, 2024
Orly Leiva @LeivaOrly @UChicagoMed shares findings from a study of the prognostic implications of pulmonary hypertension in MPN and predictors of hematologic progression (N = 555).
Among pts with MPN, PH was associated with increased risk of… pic.twitter.com/0jTOcRUANf
CONGRESS | #ASH24 | PRESENTATION@MKremyanskaya @mountsinaiNYC presented initial results of the phase I/II SANRECO trial of divesiran in patients with Polycythemia Vera. Preliminary results showed that divesiran was safe and well tolerated at doses up to 9 mg/kg.
— MPN_Hub (@MPN_Hub) December 9, 2024
Follow our live… pic.twitter.com/fDBkudvmgz
CONGRESS | #ASH24 | POSTER
— MPN_Hub (@MPN_Hub) December 9, 2024
Long Chang, Peking Union Medical College Hospital, shares findings from a study of high resolution chest computed tomography responses for a cohort of Erdheim–Chester Disease (ECD) patients with pulmonary Involvement (N = 33).
Patients with BRAFV600E… pic.twitter.com/YePn9SjQyl
CONGRESS | #ASH24 | PRESENTATION@FirasElChaer, @UVA, shared findings from an ongoing phase I/II trial (NCT04176198) of nuvisertib monotherapy in patients with R/R MF (N=65). The treatment was well tolerated, with no DLTs reported. Among 18 evaluable patients receiving the… pic.twitter.com/TEbVub8BnG
— MPN_Hub (@MPN_Hub) December 9, 2024
CONGRESS | #ASH24 | PRESENTATION
— MPN_Hub (@MPN_Hub) December 9, 2024
Daniel DeAngelo @DanaFarber shared results of the phase II APEX trial of bezuclastinib in patients with advanced systemic mastocytosis.
Bezuclastinib demonstrated encouraging safety profile and promising efficacy outcomes with deep reductions in… pic.twitter.com/MSRVo254CH
CONGRESS | #ASH24 | PRESENTATION
— MPN_Hub (@MPN_Hub) December 10, 2024
Alexandros Rampotas, UCL Cancer Institute, presents findings from pre-clinical validation of a pioneering CAR-T therapy targeting mutCALR, including efficacy in relevant clinical settings.
The novel CAR-T showed potent and highly selective… pic.twitter.com/YuWjCveV3R
CONGRESS | #ASH24 | PRESENTATION
— MPN_Hub (@MPN_Hub) December 9, 2024
Johannes Luebke, @UniHeidelberg, discussed prognostic impact of KIT inhibition and development of a contemporary risk score for patients with KIT D816V-positive advanced systemic mastocytosis (N=229). KIT inhibitor-treated patients had… pic.twitter.com/3OSYugJCpo
CONGRESS | #ASH24 | PRESENTATION
— MPN_Hub (@MPN_Hub) December 10, 2024
Claire Harrison @harrisoncn1 @GSTTnhs shares findings from the ongoing phase II RESTORE trial investigating elritercept as monotherapy and in combination with ruxolitinib in pts with MF (safety evaluable N = 73).
Improvements in Hgb and… pic.twitter.com/JcQEksAFDO
CONGRESS | #ASH24 | PRESENTATION
— MPN_Hub (@MPN_Hub) December 10, 2024
Benjamin Rolles @DrRolles @BrighamHeme @BrighamResearch @HarvardMed shares findings from a preclinical study of mutation-specific differences in the relationship between obesity and clonal hematopoiesis, with a focus on JAK2V617F and MPN… pic.twitter.com/jPOl3dcYBL
CONGRESS | #ASH24 | PRESENTATION
— MPN_Hub (@MPN_Hub) December 10, 2024
John Mascarenhas @IcahnMountSinai shares a trial update from the phase I/IB IMproveMF trial an evaluating the safety, pharmacokinetics, and clinical activity of imetelstat with ruxolitinib in patients with Intermediate-1, Intermediate-2, or… pic.twitter.com/MhabGSi64s
CONGRESS | #ASH24 | PRESENTATION
— MPN_Hub (@MPN_Hub) December 10, 2024
Lucia Masarova @MDmasarova @MDAndersonNews shares findings from a phase IB study of add on therapy with CK0804 in participants with MF and response to ruxolitinib (safety run-in N = 9).
This preliminary analysis of the run-in phase evaluating… pic.twitter.com/agowSReJM2
CONGRESS | #ASH24 | PRESENTATION
— MPN_Hub (@MPN_Hub) December 10, 2024
Peter Tan, One Clinical Research Pty Ltd, presents the study design and preliminary data from a phase I/IIa study of PXS-5505 and ruxolitinib in patients with primary, post- PV or post-ET myelofibrosis (N = 16).
Results from this trial using a… pic.twitter.com/3eSWWYpr99
CONGRESS | #ASH24 | PRESENTATION
— MPN_Hub (@MPN_Hub) December 10, 2024
Minghui Duan, Peking Union Medical College Hospital, shares interim findings from a phase II study investigating the efficacy and safety of selinexor in combination with ruxolitinib in ruxolitinib-treated patients with MF (N = 38).
The… pic.twitter.com/4GHvRI1ryO
CONGRESS | #ASH24 | PRESENTATION
— MPN_Hub (@MPN_Hub) December 10, 2024
Hany Elmariah, Moffitt Cancer Center, shares findings from a phase I trial evaluating the safety of fedratinib as a maintenance strategy after AHCT for MPN (N = 12).
Fedratinib 400mg daily was safe and identified as the MTD. The phase II… pic.twitter.com/mV4ZxhS2Mh
CONGRESS | #ASH24 | PRESENTATION
— MPN_Hub (@MPN_Hub) December 11, 2024
John Mascarenhas @IcahnMountSinai shares findings from the phase III BOREAS study investigating navtemadlin vs BAT in JAK inhibitor R/R MF (N = 183).
Navtemadlin monotherapy was safe and effective, demonstrating clinically relevant efficacy… pic.twitter.com/iyWn7Ppi5s
Related articles
Newsletter
Subscribe to get the best content related to MPN delivered to your inbox